In CHOICE (NCT00109161), add-on subcutaneous high-dose daclizumab (2 mg/kg every 2 weeks, n = 75) could significantly reduce the number of new/enlarged gadolinium-enhanced lesions (GELs) (= pSE) in MS patients (92% relapsing–remitting MS (RRMS), 8% SPMS) with active disease despite treatment with interferon beta (IFNβ) compared to IFNβ alone (n = 77) and add-on low dose daclizumab (1 mg/kg every 4 weeks; n = 78) [31]. This evidence concerns the gene IFNB1 and myeloid sarcoma.